Shenzhen YHLO Biotech (688575) H2 2024 earnings summary

Executive summary

• Revenue for 2024 was ¥1,991.68 million, down 2.99% year-over-year; net profit attributable to shareholders was ¥301.67 million, down 15.03%.

• Excluding non-recurring items, net profit rose 31.16% year-over-year, driven by strong growth in core businesses.

• Fourth quarter revenue grew 17.64% year-over-year, with net profit up 18.62%.

Financial highlights

• Operating profit for 2024 was ¥307.46 million, down 9.71% year-over-year.

• Basic EPS was ¥0.53, a decrease of 15.87% year-over-year.

• Total assets at year-end were ¥4,426.23 million, up 16.29% from the start of the year.

• Shareholders’ equity increased 7.85% year-over-year to ¥2,760.89 million.

• Net asset per share rose 7.45% to ¥4.84.

Outlook and guidance

• Core non-COVID business, especially chemiluminescence, is expected to continue strong growth.